CA1335713C - Appareil et methode pour separer les leucocytes d'un concentre de plaquettes - Google Patents

Appareil et methode pour separer les leucocytes d'un concentre de plaquettes

Info

Publication number: CA1335713C
Authority: CA; Canada
Prior art keywords: platelet concentrate; depletion; passing; platelet; medium
Prior art date: 1988-02-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000590573A

Other languages

English (en)

Inventor

David Boris Pall

Thomas Charles Gsell

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pall Corp

Original Assignee

Pall Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-02-17

Filing date

1989-02-09

Publication date

1995-05-30

1989-02-09 Application filed by Pall Corp filed Critical Pall Corp

1995-05-30 Application granted granted Critical

1995-05-30 Publication of CA1335713C publication Critical patent/CA1335713C/fr

2012-05-30 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000003634 thrombocyte concentrate Substances 0.000 title claims abstract description 232
238000000034 method Methods 0.000 title claims abstract description 116
210000000265 leukocyte Anatomy 0.000 claims abstract description 190
239000000835 fiber Substances 0.000 claims description 159
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims description 60
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical group CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 59
239000000243 solution Substances 0.000 claims description 58
239000011148 porous material Substances 0.000 claims description 56
239000000178 monomer Substances 0.000 claims description 52
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 44
210000004369 blood Anatomy 0.000 claims description 35
239000008280 blood Substances 0.000 claims description 35
239000012530 fluid Substances 0.000 claims description 34
239000007788 liquid Substances 0.000 claims description 32
239000002253 acid Substances 0.000 claims description 23
239000000203 mixture Substances 0.000 claims description 19
229920001707 polybutylene terephthalate Polymers 0.000 claims description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
-1 polybutylene terephthalate Polymers 0.000 claims description 16
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
238000012986 modification Methods 0.000 claims description 15
230000004048 modification Effects 0.000 claims description 15
238000004519 manufacturing process Methods 0.000 claims description 14
230000008569 process Effects 0.000 claims description 12
125000000129 anionic group Chemical group 0.000 claims description 11
230000006835 compression Effects 0.000 claims description 11
238000007906 compression Methods 0.000 claims description 11
OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical group [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 claims description 11
239000012503 blood component Substances 0.000 claims description 10
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 9
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 9
238000011144 upstream manufacturing Methods 0.000 claims description 9
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 7
230000008859 change Effects 0.000 claims description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
239000007864 aqueous solution Substances 0.000 claims description 4
150000001767 cationic compounds Chemical class 0.000 claims description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
125000005395 methacrylic acid group Chemical group 0.000 claims description 4
238000011045 prefiltration Methods 0.000 claims description 4
POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 claims description 3
229940028356 diethylene glycol monobutyl ether Drugs 0.000 claims description 3
JCGNDDUYTRNOFT-UHFFFAOYSA-N oxolane-2,4-dione Chemical group O=C1COC(=O)C1 JCGNDDUYTRNOFT-UHFFFAOYSA-N 0.000 claims description 3
238000006116 polymerization reaction Methods 0.000 claims description 3
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
125000002843 carboxylic acid group Chemical group 0.000 claims 1
238000009736 wetting Methods 0.000 abstract description 16
238000012360 testing method Methods 0.000 description 73
238000011084 recovery Methods 0.000 description 70
239000000975 dye Substances 0.000 description 27
239000000047 product Substances 0.000 description 26
239000000306 component Substances 0.000 description 15
238000009826 distribution Methods 0.000 description 15
238000011161 development Methods 0.000 description 14
238000001179 sorption measurement Methods 0.000 description 14
238000001914 filtration Methods 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
230000037452 priming Effects 0.000 description 12
239000002245 particle Substances 0.000 description 11
230000005855 radiation Effects 0.000 description 11
229920005989 resin Polymers 0.000 description 11
239000011347 resin Substances 0.000 description 11
210000004027 cell Anatomy 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
238000000926 separation method Methods 0.000 description 9
239000000463 material Substances 0.000 description 8
230000009467 reduction Effects 0.000 description 8
239000000725 suspension Substances 0.000 description 8
238000007664 blowing Methods 0.000 description 7
230000006870 function Effects 0.000 description 7
210000002381 plasma Anatomy 0.000 description 7
229920000728 polyester Polymers 0.000 description 7
229920002994 synthetic fiber Polymers 0.000 description 7
239000012209 synthetic fiber Substances 0.000 description 7
206010037660 Pyrexia Diseases 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
230000000875 corresponding effect Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000006872 improvement Effects 0.000 description 6
238000005259 measurement Methods 0.000 description 6
206010060935 Alloimmunisation Diseases 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
230000000712 assembly Effects 0.000 description 5
238000000429 assembly Methods 0.000 description 5
239000012141 concentrate Substances 0.000 description 5
230000007423 decrease Effects 0.000 description 5
229920001343 polytetrafluoroethylene Polymers 0.000 description 5
239000004810 polytetrafluoroethylene Substances 0.000 description 5
108010073385 Fibrin Proteins 0.000 description 4
102000009123 Fibrin Human genes 0.000 description 4
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
230000002411 adverse Effects 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
230000001276 controlling effect Effects 0.000 description 4
238000013461 design Methods 0.000 description 4
229950003499 fibrin Drugs 0.000 description 4
239000000499 gel Substances 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
229920006395 saturated elastomer Chemical group 0.000 description 4
239000007787 solid Substances 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108010049003 Fibrinogen Proteins 0.000 description 3
102000008946 Fibrinogen Human genes 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000000427 antigen Substances 0.000 description 3
238000002617 apheresis Methods 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000010276 construction Methods 0.000 description 3
238000011109 contamination Methods 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000000428 dust Substances 0.000 description 3
229940012952 fibrinogen Drugs 0.000 description 3
239000007789 gas Substances 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000010410 layer Substances 0.000 description 3
239000000155 melt Substances 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
210000004623 platelet-rich plasma Anatomy 0.000 description 3
230000002265 prevention Effects 0.000 description 3
238000003908 quality control method Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
238000007789 sealing Methods 0.000 description 3
XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
230000002269 spontaneous effect Effects 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
206010043554 thrombocytopenia Diseases 0.000 description 3
230000003582 thrombocytopenic effect Effects 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
206010002961 Aplasia Diseases 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
229920002292 Nylon 6 Polymers 0.000 description 2
239000004952 Polyamide Substances 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
239000004743 Polypropylene Substances 0.000 description 2
208000003441 Transfusion reaction Diseases 0.000 description 2
229920006397 acrylic thermoplastic Polymers 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
230000036770 blood supply Effects 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
229920002301 cellulose acetate Polymers 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
238000005520 cutting process Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000011049 filling Methods 0.000 description 2
230000005484 gravity Effects 0.000 description 2
230000023597 hemostasis Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
208000014674 injury Diseases 0.000 description 2
239000006194 liquid suspension Substances 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
229920002647 polyamide Polymers 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
229920000139 polyethylene terephthalate Polymers 0.000 description 2
239000005020 polyethylene terephthalate Substances 0.000 description 2
229920001155 polypropylene Polymers 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
125000001453 quaternary ammonium group Chemical group 0.000 description 2
VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
238000002798 spectrophotometry method Methods 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
239000007858 starting material Substances 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
229920003002 synthetic resin Polymers 0.000 description 2
239000000057 synthetic resin Substances 0.000 description 2
ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
230000035899 viability Effects 0.000 description 2
238000000733 zeta-potential measurement Methods 0.000 description 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 description 1
QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 description 1
229920000178 Acrylic resin Polymers 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
208000037157 Azotemia Diseases 0.000 description 1
108010039209 Blood Coagulation Factors Proteins 0.000 description 1
102000015081 Blood Coagulation Factors Human genes 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
229920000742 Cotton Polymers 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
206010073306 Exposure to radiation Diseases 0.000 description 1
208000013607 Glanzmann thrombasthenia Diseases 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
101000621371 Homo sapiens WD and tetratricopeptide repeats protein 1 Proteins 0.000 description 1
101000892274 Human adenovirus C serotype 2 Adenovirus death protein Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
229920002302 Nylon 6,6 Polymers 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
108010000020 Platelet Factor 3 Proteins 0.000 description 1
206010073391 Platelet dysfunction Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
101000820656 Rattus norvegicus Seminal vesicle secretory protein 4 Proteins 0.000 description 1
108010081391 Ristocetin Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
206010064390 Tumour invasion Diseases 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
206010047139 Vasoconstriction Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000027276 Von Willebrand disease Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229920003235 aromatic polyamide Polymers 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000003114 blood coagulation factor Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
229920006317 cationic polymer Polymers 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 1
208000035850 clinical syndrome Diseases 0.000 description 1
229910017052 cobalt Inorganic materials 0.000 description 1
239000010941 cobalt Substances 0.000 description 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
230000001427 coherent effect Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
230000000779 depleting effect Effects 0.000 description 1
238000000151 deposition Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
238000001085 differential centrifugation Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000001206 effect on leukocytes Effects 0.000 description 1
230000005684 electric field Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
125000003700 epoxy group Chemical group 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000012632 extractable Substances 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
239000000413 hydrolysate Substances 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229910052738 indium Inorganic materials 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000001746 injection moulding Methods 0.000 description 1
238000007689 inspection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920002239 polyacrylonitrile Polymers 0.000 description 1
229920005668 polycarbonate resin Polymers 0.000 description 1
239000004431 polycarbonate resin Substances 0.000 description 1
229920000306 polymethylpentene Polymers 0.000 description 1
239000011116 polymethylpentene Substances 0.000 description 1
229920005990 polystyrene resin Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
238000011176 pooling Methods 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
238000002310 reflectometry Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
229950004257 ristocetin Drugs 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000001878 scanning electron micrograph Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000004317 sodium nitrate Substances 0.000 description 1
235000010344 sodium nitrate Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
125000000542 sulfonic acid group Chemical group 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000012815 thermoplastic material Substances 0.000 description 1
DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
238000011282 treatment Methods 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1
208000009852 uremia Diseases 0.000 description 1
230000002227 vasoactive effect Effects 0.000 description 1
230000025033 vasoconstriction Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 1
238000003466 welding Methods 0.000 description 1

Landscapes

External Artificial Organs (AREA)

CA000590573A 1988-02-17 1989-02-09 Appareil et methode pour separer les leucocytes d'un concentre de plaquettes Expired - Lifetime CA1335713C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15689488A	1988-02-17	1988-02-17
US07/156,894		1988-02-17

Publications (1)

Publication Number	Publication Date
CA1335713C true CA1335713C (fr)	1995-05-30

Family

ID=22561548

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000590573A Expired - Lifetime CA1335713C (fr)	1988-02-17	1989-02-09	Appareil et methode pour separer les leucocytes d'un concentre de plaquettes

Country Status (3)

Country	Link
JP (1)	JPH0642906B2 (fr)
CA (1)	CA1335713C (fr)
ZA (1)	ZA891170B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE193454T1 (de) *	1989-09-12	2000-06-15	Pall Corp	Verfahren und vorrichtung zur behandlung von menschlichem blut für die transfusion
DE69319471T2 (de) *	1992-03-17	1999-04-15	Asahi Medical Co. Ltd., Tokio/Tokyo	Filtermedium mit begrenzter negativer Oberflächenladung für die Behandlung von Blutmaterial
EP0606646B1 (fr) *	1992-12-28	1997-09-24	Asahi Medical Co., Ltd.	Matériau filtrant, dispositif et méthode pour la séparation de leucocytes
JP3246620B2 (ja) *	1993-02-22	2002-01-15	旭メディカル株式会社	白血球除去フィルター支持体
CN1177620C (zh)	1997-08-28	2004-12-01	旭医学株式会社	除白细胞的过滤介质
ITTO20020736A1 (it) *	2002-08-21	2004-02-22	Fresenius Hemocare Italia Srl	Filtro per leucociti e suo impiego per l'impoverimento di prodotti del sangue da leucociti.
JP5784008B2 (ja)	2010-03-31	2015-09-24	旭化成メディカル株式会社	リガンド固定化用基材及びその製造方法
CN103712928A (zh) *	2013-12-05	2014-04-09	同济大学	一种测定污水中阴离子表面活性剂浓度的检测剂
WO2021054192A1 (fr)	2019-09-20	2021-03-25	富士フイルム株式会社	Tissu non tissé, procédé de production d'un tissu non tissé, et filtre
EP4721776A1 (fr) *	2023-06-16	2026-04-08	Terumo Kabushiki Kaisha	Dispositif de filtre
WO2024257880A1 (fr) *	2023-06-16	2024-12-19	テルモ株式会社	Dispositif de filtre

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5446811A (en) *	1977-09-20	1979-04-13	Asahi Chem Ind Co Ltd	Method for removing leukocytes from blood
JPS5523805A (en) *	1978-08-03	1980-02-20	Iwao Fukuda	Heater
JPS60203267A (ja) *	1984-03-27	1985-10-14	旭メデイカル株式会社	白血球除去用フイルタ−装置
JPS61106640A (ja) *	1984-10-30	1986-05-24	Toa Nenryo Kogyo Kk	親水性ポリエチレン微多孔膜

1989
- 1989-02-09 CA CA000590573A patent/CA1335713C/fr not_active Expired - Lifetime
- 1989-02-15 ZA ZA891170A patent/ZA891170B/xx unknown
- 1989-02-17 JP JP1038160A patent/JPH0642906B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPH0642906B2 (ja)	1994-06-08
JPH01249063A (ja)	1989-10-04
ZA891170B (en)	1989-11-29

Legal Events

Date	Code	Title	Description
2012-05-30	MKEX	Expiry

Publication	Publication Date	Title
EP0329303B2 (fr)	2001-09-26	Appareil et méthode pour la séparation de leucocytes à partir d'un concentrat de sang
US5344561A (en)	1994-09-06	Device for depletion of the leucocyte content of blood and blood components
JP2555722B2 (ja)	1996-11-20	血液および血液成分の白血球含量を低下させるための装置および方法
US5229012A (en)	1993-07-20	Method for depletion of the leucocyte content of blood and blood components
JP2541340B2 (ja)	1996-10-09	血液および血液成分の白血球含量を低下させる装置および方法
US4925572A (en)	1990-05-15	Device and method for depletion of the leukocyte content of blood and blood components
US4923620A (en)	1990-05-08	Device for depletion of the leukocyte content of blood and blood components
EP1582228B1 (fr)	2016-04-13	Procede d'elimination de leucocytes, filtre servant a eliminer les leucocytes et son utilisation
US4976861A (en)	1990-12-11	Method for determining the wetting characteristic of a porous medium
CA1335713C (fr)	1995-05-30	Appareil et methode pour separer les leucocytes d'un concentre de plaquettes
US7217365B2 (en)	2007-05-15	Blood filtration methods
GB2246432A (en)	1992-01-29	Testing filter media
IL108261A (en)	1996-10-31	Method and device for treating blood or blood component
AU624095B2 (en)	1992-06-04	Depletion of leukocyte from blood
GB2248193A (en)	1992-04-01	Blood filter
IL106893A (en)	1996-05-14	Method and device for separating material (sea) from a liquid intended for insertion into a patient